French 2013 guidelines for antiretroviral therapy of HIV‐1 infection in adults
In: Journal of the International AIDS Society, Band 17, Heft 1
ISSN: 1758-2652
IntroductionThese guidelines are part of the French Experts' recommendations for the management of people living with HIV/AIDS, which were made public and submitted to the French health authorities in September 2013. The objective was to provide updated recommendations for antiretroviral treatment (ART) of HIV‐positive adults. Guidelines included the following topics: when to start, what to start, specific situations for the choice of the first session of antiretroviral therapy, optimization of antiretroviral therapy after virologic suppression, and management of virologic failure.MethodsTen members of the French HIV 2013 expert group were responsible for guidelines on ART. They systematically reviewed the most recent literature. The chairman of the subgroup was responsible for drafting the guidelines, which were subsequently discussed within, and finalized by the whole expert group to obtain a consensus. Recommendations were graded for strength and level of evidence using predefined criteria. Economic considerations were part of the decision‐making process for selecting preferred first‐line options. Potential conflicts of interest were actively managed throughout the whole process.ResultsART should be initiated in any HIV‐positive person, whatever his/her CD4 T‐cell count, even when >500/mm3. The level of evidence of the individual benefit of ART in terms of mortality or progression to AIDS increases with decreasing CD4 cell count. Preferred initial regimens include two nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine or abacavir/lamivudine) plus a non‐nucleoside reverse transcriptase inhibitor (efavirenz or rilpivirine), or a ritonavir‐boosted protease inhibitor (atazanavir or darunavir). Raltegravir, lopinavir/r, and nevirapine are recommended as alternative third agents, with specific indications and restrictions. Specific situations such as HIV infection in women, primary HIV infection, severe immune suppression with or without identified opportunistic infection, and person who injects drugs are addressed. Options for optimization of ART once virologic suppression is achieved are discussed. Evaluation and management of virologic failure are described, the aim of any intervention in such situation being to reduce plasma viral load to <50 copies/ml.ConclusionThese guidelines recommend that any HIV‐positive individual should be treated with ART. This recommendation was issued both for the patient's own sake and for promoting treatment as prevention.
